





























Link to publication record in King's Research Portal
Citation for published version (APA):
Longhi, M. S., Robson, S. C., Bernstein, S. H., Serra, S., & Deaglio, S. (2013). Biological functions of ecto-
enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states. Journal of
molecular medicine (Berlin, Germany), 91(2), 165-172. 10.1007/s00109-012-0991-z
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
1 
 
Biological functions of ecto-enzymes in regulating extracellular adenosine 
levels in neoplastic and inflammatory disease states. 
 
Maria Serena Longhi*, Simon C Robson, Steven H. Bernstein, Sara Serra and Silvia 
Deaglio*  
 
Maria Serena Longhi 
Affiliation: Institute of Liver Studies, King’s College London School of Medicine at 
King’s College Hospital, Denmark Hill SE5 9RS, London, United Kingdom. 
 
Simon C Robson 
Affiliation:  Division of Gastroenterology, and Transplant Institute, Department of 
Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston 02215, 
USA. 
 
Steven H. Bernstein. 
Affiliation: James P. Wilmot Cancer Center, University of Rochester Medical Center, 
Rochester, NY 14642, USA. 
 
Sara Serra and Silvia Deaglio  
Human Genetics Foundation (HuGeF) & Department of Medical Sciences, University 




Silvia Deaglio MD, PhD 
Human Genetics Foundation (HuGeF)  
Department of Medical Sciences 
University of Turin, Turin, Italy 
& 
Maria Serena Longhi, MD, PhD 
Institute of Liver Studies  
King’s College London School of Medicine 
at King’s College Hospital  
Denmark Hill  
London SE5 9RS, United Kingdom 
Email: maria.longhi@kcl.ac.uk  
Tel: +44(0) 203299 3397; Fax: +44(0) 203299 3760 
 
Acknowledgements: The work summarized in this review article was supported by: 
Clinician Scientist Fellowship from the Medical Research Council (UK); National 
Institute of Health; R01 HL094400; P01HL107152, P01 HL087203 and P01 
AI045897 and Associazione Italiana Ricerca Cancro (IG #12754); Italian Ministries of 
Health (Bando Giovani Ricercatori 2008) and Education (Bando FIRB Giovani 2008 






When present in the extracellular environment, the nucleoside adenosine protects 
cells and tissues from excessive inflammation and immune-mediated damage, while 
promoting healing processes. This role has been highlighted experimentally using 
distinct disease models, including those of colitis, diabetes, asthma, sepsis, and 
ischemic injury. Adenosine also suppresses immune responses, as in the tumor 
microenvironment, assisting immune evasion while promoting angiogenesis. The 
mechanisms involved in adenosine signaling are addressed elsewhere in this issue. 
Here, the authors specifically address the generation of adenosine from extracellular 
nucleotides. This process is catalyzed by series of plasma membrane 
ectonucleotidases, with the focus in this article on members of the CD39, CD73 and 
CD38 families and on their role in inflammatory and neoplastic hematological 
diseases. Pharmacological modulation of adenosine generation by drugs that either 






Adenosine is a purine nucleoside comprising a molecule of adenine attached to a 
ribose sugar molecule moiety via glycosidic bonds. When present in the extracellular 
environment, this mediator protects cells and tissues from excessive immune-
mediated damage. This role has been highlighted recently in several disease 
models, including colitis [1], diabetes [2], asthma [3], sepsis [4], and ischemic injury 
[5]. Adenosine also suppresses immune responses, and as such, may mediate in 
part, the immune-suppression often seen within the tumor microenvironment thus 
facilitating tumor immune evasion [6]. Therefore, mechanisms involved in both the 
generation of adenosine as well as its downstream signaling pathways are of 
considerable therapeutic interest [7].  
 
Purinergic Signaling 
Under normal physiologic conditions, the levels of adenosine in the tissue 
microenvironment are relatively low, and certainly below the sensitivity threshold of 
immune cells. However, during hypoxia, ischemia, inflammation, infection, metabolic 
stress and tumor transformation tissue adenosine levels rapidly increase [8]. These 
elevated levels of extracellular adenosine in response to tissue-disturbing signals 
has the dual function of signaling tissue injury in an autocrine and paracrine manner 
and eliciting a range of tissue responses that can be generally viewed as organ 
protective. 
Growing evidence indicates that in addition to the nucleoside adenosine, 
extracellular nucleotides, such as adenosine triphosphate (ATP) or nicotinamide 




Extracellular ATP binds multiple type-2 purinergic/pyrimidinergic (P2Y and P2X) 
receptors, and this interaction influences cellular metabolism, migration, proliferation 
and apoptosis [reviewed in [10],[11]]. This nucleotide may also serve as substrates 
for ectonucleotidases, surface enzymes having their catalytic domain located in the 
extracellular compartment.  
The most well characterized ectonucleotidase pathway proceeds through the 
sequential action of CD39 (ectonucleoside triphosphate diphosphohydrolase-1, 
ENTPD-1), the prototype of the ENTPD-ase enzyme family, which converts 
extracellular ATP (or ADP) to AMP. CD39 is located on the cell surface and contains 
one extracellular facing catalytic domain and two transmembrane domains, important 
for maintaining catalytic activity and substrate specificity [12]. The ectonucleotidase 
cascade initiated by CD39 is terminated by CD73 (5’-nucleotidase) that converts 
AMP to adenosine [13]. CD73 is a dimeric extracellular glycoprotein tethered to the 
cell membrane by a glycosyl phosphatidyl inositol anchor. Alternatively, adenosine 
can be generated from NAD through to the coordinated action of CD38 (NAD 
glycohydrolase), which generates ADP ribose (ADPR), and PC-1 (ectonucleotide 
pyrophosphatase / phosphodiesterase family member 1), which generates AMP. The 
removal of the final phosphate is operative via CD73, which consequently acts as a 
bottleneck enzyme in the setting of both cascades. 
Adenosine elicits its physiological responses by binding to and activating one or 
more of the four transmembrane adenosine receptors, denoted A1, A2A, A2B and 
A3. Each of these four adenosine receptor subtypes is coupled to a G-protein, which 
can stimulate (Gs protein) or inhibit (Gi protein) the production of intracellular cAMP. 
Changes in the levels of cAMP influence the activity of intracellular protein kinases 
that phosphorylate intracellular proteins or transmembrane ion channels during 
6 
 
physiological responses [14]. Adenosine at physiological levels (below 1 µM) can 
activate A1, A2A and A3 adenosine receptors, whereas much higher concentrations 
of this nucleoside (i.e. generated under pathophysiological conditions) are required 
to stimulate the A2B adenosine receptor. 
 
Transcriptional regulation of ecto-enzyme expression 
The expression of the CD39 and CD73 ecto-enzymes can be regulated by hypoxia 
or by exposure to cytokines present in the extra-cellular milieu.  
A study from Synnestvedt et al demonstrated that hypoxia was able to induce CD39 
and CD73 expression and function [15]. In this same study, analysis of the CD73 
gene promoter region revealed one binding site for hypoxia-inducible factor 1 (HIF-1) 
[15] suggesting that hypoxia may regulate CD73 expression through HIF-1.  
In the context of colitis, induction of CD39 and CD73 by hypoxia resulted in a shift 
from pro-inflammatory ATP to immunosuppressive adenosine [16]. A study from 
Cummins et al examined the effect of dimethyl oxalyl glycine (DMOG), an 
hydroxylase inhibitor, on Caco-2 intestinal cells and reported that DMOG was able to 
induce HIF-1 and protect mice from dextran sodium solfate (DSS)-induced colitis 
[17].  In another study, Robinson and co-workers evaluated the effect of FG-4497, 
another hydroxylase inhibitor, on murine colitis induced by trinitrobenzene sulfonic 
acid (TNBS). FG-4497 induced HIF-1 and attenuated clinical symptoms of colitis 
[18]. Both investigations suggest that HIF-1 activators could be beneficial to hypoxia-
induced tissue inflammation through the generation of the immune-suppressive 
adenosine.  
Regulation of ecto-enzymes expression has been also linked to the cytokine milieu 
that cells are exposed to. Thus in a study from Regateiro et al, expression of CD73 
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on murine CD4+ T cells resulted in the hydrolysis of AMP and the subsequent 
generation of adenosine that in turn could suppress the proliferation of effector CD4 
T cells in vitro. In the same study, the authors reported that TGF-β also induced 
CD73 on CD8+ T cells, macrophages and dendritic cells, thereby enabling adenosine 
to be generated in different tissue microenvironments [19].  
In the tumor setting Sekar et al reported that apoptotic tumor cells induce IL-27 
secretion by dendritic cells which activates CD39+CD69+ regulatory T cells. They 
further postulate that the expression of CD69 on such cells facilitates the interaction 
of CD39+ regulatory T cells with CD73+ CD8 cells resulting in the generation of 
adenosine, therefore suppressing CD8 T cell cytotoxicity [20].   
 
Ectonucleotidases, Adenosine Generation and Immunosuppression 
In mouse systems, circulating CD4+/CD25high regulatory T lymphocytes have been 
shown to express high levels of functional CD39 and CD73 thus having the capacity 
to generate adenosine. Furthermore, adenosine production is an integral component 
of the suppressive machinery of regulatory T cells. Under conditions of chronic 
inflammation, considerable amounts of ATP are released in the extracellular 
environment, while at the same time activated effector T cells express the A2A 
receptor. Adenosine production is thus believed to be a late mechanism for 
controlling effector T cell proliferation mainly in chronically activated or inflamed 
tissues.  
The situation in humans is more complicated, with the circulating component of 
regulatory T cells constitutively expressing CD39+ but not CD73-. Therefore, such 
regulatory T-cells are unable to produce adenosine. CD73 expression is however 
rapidly turned on under activation and as such, regulatory T cells infiltrating solid 
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tumors, for example, appear to be CD39+/CD73+, and therefore would be expected 
to be able to generate adenosine locally in the tumor microenvironment.   
 
Cancer 
Extracellular adenosine is elevated in neoplastic tissues as consequence of an 
increased expression and activity of the ecto-enzymes that produce it. Several types 
of solid tumors [21],[22] and certain types of leukemia [23],[24] express the 
enzymatic machinery necessary to convert ATP into adenosine on their cell surface. 
Accumulation of adenosine within the tumor tissue has complex and diverse effects. 
On the one side, this nucleoside has been linked to cytoprotection and growth 
promotion of tumor cells. On the other side, adenosine has a profound impact on the 
environment surrounding the tumor. Indeed, this nucleoside may increase 
angiogenesis, inhibit Th1 cytokine production, promote adhesion of immune cells to 
endothelial cells and contribute to suppression of effector T cells [reviewed in [25]]. 
Based on this knowledge, an intriguing possibility is that tumor cells themselves may 
exploit the CD39/CD73 enzymatic cascade to actively produce adenosine and 
favorably modify its local environment.  
We have recently examined these possibilities in mouse models of metastatic 
disease and melanoma [26], and in human chronic lymphocytic leukemia (CLL) In a 
comparable manner, recently Salvestrini and co-workers [27] have highlighted the 
significance of purinergic signaling in the inhibition of cell proliferation, homing and 
engraftment of tumor cells in a murine model of acute myeloblastic leukemia (AML) 
[27]. 
We will next address the clinical relevance of the role of purinergic signaling in CLL 
and other hematological malignancies, such as follicular lymphoma. 
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Chronic Lymphocytic Leukemia (CLL) 
This chronic leukemia, characterized by the expansion of a mature population of 
CD5+/CD23+ B lymphocytes, displays markedly different behaviors whether in the 
blood or in the LN, with proliferation occurring almost exclusively in the latter [28-30]. 
Circulating CLL cells are characterized by an invariably high expression of CD39 and 
a variable CD73 expression. Approximately 30% of CLL patients express high levels 
of CD73 on their leukemic cells and this is associated with such cellular markers of 
poor prognosis as CD38 and ZAP-70. Immunohistochemical analysis of lymph node 
tissues indicates that the highest intensity of CD73 expression is near the CLL 
proliferation centers. Furthermore, CD73+ lymphocytes are generally Ki-67+ 
proliferating cells, which are in close contact with CD2+ T lymphocytes. These 
arrangements appear essential for the expansion of the pathogenic CLL clones, 
which in turn localize adjacent to perivascular areas [24].  
Together, these observations indicate that CD73 expression on neoplastic CLL cells 
is associated with more aggressive clinical behavior, higher cellular turnover and 
intense recirculation to and from lymphoid organs. 
Analysis of the enzymatic activities on purified CLL cells indicates that this enzymatic 
cascade is highly functional. Indeed, CD39+/CD73+ cells can actively convert the 
substrate ADP to AMP and to the final product adenosine. Because circulating CLL 
lymphocytes constitutively express significantly higher levels of the A2A adenosine 
receptor as compared to age- and sex-matched controls, adenosine binding to these 
receptors (or activation through a selective A2A agonist) leads to increases in 




These data indicate the existence of an autocrine adenosinergic loop in a selected 
subset of CLL patients, where adenosine is produced and then consumed by 
leukemic cells. The activation of this axis modulates chemotactic responses of CLL 
cells, for example inhibiting CXCL12 chemokine induced migration, and protects 
such cells from spontaneous or drug-induced apoptosis. Exposure of CLL cells to a 
commercially available CD73 inhibitor as well as to selective adenosine receptor 
agonists or antagonists confirm that these effects are directly mediated by CD73-
generated extracellular adenosine and by the A2A receptor [24]. 
These observations suggest that in CLL cells, CD73 might be a major modulatory 
ecto-enzyme in the activation of the adenosinergic axis. Further, adenosine 
production is restricted by CD73 expression, hence mostly confined in sites of higher 
cellular turnover, like the lymph node proliferation centers. In the CLL model, CD73 
expression, increased levels of extracellular nucleotides and adenosine generation 
may cooperate together to create local microenvironmental conditions that favor the 
survival of the leukemic clone and partially protect the clone from the action of 
chemotherapy. Therefore, targeting the adenosinergic axis might have important 




Hilchey and co-workers [23], have demonstrated that human follicular lymphoma 
(FL) infiltrating T lymphocytes are anergic, due in part to regulatory T-cell 
suppression mediated through an adenosine-dependent pathway. Indeed, 
extracellular adenosine, by activating purinergic A2A and A2B receptors expressed 
by FL infiltrating effector T cells, in part, mediates FL infiltrating T cell hypo-
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responsiveness in a subset of patient samples. In this system, inhibition of the ATP-
ectonucleotidase-adenosine axis with putative CD39 inhibitors, e.g. ARL67156 or 
with specific A2A and A2B receptor antagonists, partially overcomes the T cell hypo-
responsiveness to stimulation seen with untreated single cell suspensions derived 
from FL lymph nodes.  Specifically, a significant increase in INF-gamma and IL-2 
production is observed in stimulated FL lymph node mononuclear cells, compared to 
that seen in stimulated normal lymph node mononuclear cells, when either CD39 or 
A2A/A2B receptor signaling is inhibited. Consistent with these observations, the 
proportion of CD4+ T-cells that express CD39 is higher in lymph node biopsies from 
FL patients as compared to that of normal or reactive lymph nodes or to peripheral 
blood from normal donors. Furthermore, a proportion of these CD39+ T-cells express 
the classical phenotype of T regulatory cells (CD4+/CD25high/FOXP3+). 
These results indicate that adenosine may play an important role in FL-mediated 
immunosuppression and that the ATP-ectonucleotidase-adenosine axis could be a 
relevant pharmacological target for cancer immunotherapy [23],[31]. 
 
The Figure illustrates the role of the ecto-enzyme network in cancer models. 
 
Asthma, chronic obstructive pulmonary disorder and acute lung injury 
A number of studies have supported the evidence that adenosine signaling is 
involved in the pathophysiology of asthma and chronic obstructive pulmonary 
disorder (COPD). As an example, in an allergic mouse model of asthma, challenge 
with adenosine enhanced airway inflammation and led to an increase in 
lymphocytes, eosinophils, neutrophils and activated macrophages in the 
bronchoalveolar lavage (BAL) [3]. Administration of theophylline, a non-specific 
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adenosine receptor antagonist, prevented enhancement of the inflammatory infiltrate 
induced by adenosine [3]. Moreover, a wealth of studies over the years clearly 
demonstrated that adenosine can induce bronchoconstriction in patients suffering 
from asthma and COPD but not in healthy individuals. The A2B adenosine receptor 
was found to be one of the main receptors involved in mediating the stimulatory 
effect of adenosine on mast cells [32]; based on these observations the use of A2B 
receptor antagonists has been proposed to treat asthma and COPD. A study from 
Hua et al, however, reported the opposite results as they showed that the enhanced 
mast cells activation seen in mice was the result of A2B adenosine receptor loss. 
Loss of this receptor resulted in decreased cyclic AMP basal levels and the influx of 
extracellular calcium through store-operated calcium channels after activation with 
antigen [33]. Moreover, A2B-/- mice displayed increased anaphylaxis, suggesting that 
A2B adenosine receptor is a negative regulator of mast cell function [33]. 
Extracellular adenosine has been also implicated as an immunomodulatory molecule 
during acute lung injury. Previous studies have shown the presence of acute lung 
injury, particularly edema, inflammation and diminished gas exchange in mutant 
mice with CD39 deletion [34, 35]. Further work has demonstrated that deletion of the 
A2B adenosine receptor in mice with ventilation-induced lung injury (VILI) resulted in 
reduced survival time and that treatment with the A2B adenosine receptor agonist - 
BAY 60-6583 - was able to attenuate VILI-induced damage [36].  
 
Ischemia-reperfusion 
Several lines of evidence indicate that extracellular adenosine can control tissue 
damage from ischemia and reperfusion injury in several organs, including the heart, 
liver, kidney and intestine. A study from Eckle et al demonstrated the importance of 
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adenosine generation for cardioprotection by ischemic preconditioning [37]. Results 
from the same investigations showed that ischemic preconditioning led to 
cardioprotection in A1-/-, A2A-/- and A3-/- but not in A2B-/- mice and that treatment with 
an A2B adenosine receptor antagonist reduced the size of infarction induced by 
ischemia [37].  
In the renal setting, increases in adenosine by ischemic preconditioning were found 
to be attenuated in CD39-/- mice while administration of apyrase (a plasma 
membrane-bound enzyme catalysing the hydrolysis of ATP) was capable of restoring 
renal protection [38]. Similarly, no increase in adenosine generation from ischemia 
preconditioning was found in CD73-/- mice; administration of 5’-ectonucleotidase 
resulted in complete restoration of renal protection [39]. In a study from Crikis et al, 
overexpression of CD39, known to induce heightened levels of adenosine 
generation, conferred protection in a model of warm renal ischemia reperfusion [40]. 
Mice displayed reduced histological lesions, lower levels of apoptosis and preserved 
serum creatinine and urea levels. Treatment with A2A adenosine receptor antagonist 
attenuated the protective effect of CD39 overexpression [40]. In the hepatic setting 
increases in the production of adenosine were absent in CD73-/- mice and were 
restored after administration of soluble 5’-ectonucleotidase [41]. In the same context 
CD39 null mice were protected from acute vascular injury after single-lobe warm 
ischemia reperfusion injury and, compared to wild type control mice, displayed lower 
aminotransferase levels and less marked histological changes. The same 
investigation highlighted that it was CD39 deletion on hepatic NK cells that provides 
protection against ischemia reperfusion injury [42]. A subsequent study from 
Pommey et al demonstrated that liver grafts from CD39 overexpressing mice were 
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protected from ischemia reperfusion injury and that this protection was mediated by 
the absence of CD4 T cells [43].  
In a model of intestinal ischemia reperfusion, CD73-/- mice displayed lower 
adenosine levels that did not increase following ischemia reperfusion injury [44]. 
Administration of soluble 5’-ectonucleotidase was accompanied by decreased injury 
[44]. In another model of intestinal ischemia reperfusion injury CD39 null mice 
showed an increased mortality rate when compared to wild type control mice. 
Apyrase supplementation, while able to fully protect wild type mice from death, did 
not fully protect CD39 null mice [45]. 
 
Sepsis 
Extracellular levels of adenosine are high in sepsis. Studies on adenosine signaling 
have shown that genetic deficiency of the A2B receptor resulted in the increased 
mortality of such mice after cecal ligation and puncture-induced sepsis [4]. High 
levels of pro-inflammatory cytokines were similarly associated with the death of such 
mice [4].  
A recent study in humans in whom experimental endotoxemia was induced by 
intravenous injection of LPS showed modifications in adenosine metabolism and 
signaling that were associated with an increase in adenosine levels and a dose 
dependent decrease in adenosine deaminase and adenosine kinase [46].  
 
Autoimmunity 
Inflammatory Bowel Disease 
Given the immunosuppressive properties of adenosine, modulation of its signaling 
has been exploited in the context of inflammatory bowel disease (IBD) and other 
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autoimmune conditions to curb inflammation. IBD results from massive lymphocyte 
infiltration of the gut lamina propria, with T helper type 1 (Th1) [47-49] and 17 (Th17) 
cells [50-54] likely playing the major role in the perpetration of damage against the 
luminal flora.  
Alterations in the generation of adenosine, such as those associated with defects in 
CD39 or CD73 expression, led to a more severe course of the colitis. Thus, mice null 
for CD39 were highly susceptible to DSS-induced colitis, displaying dense wall 
thickening and profound lymphocytic infiltration of the colonic mucosa compared to 
that of wild type mice [55].  
In humans, a polymorphism adjacent to the CD39 promoter region has been 
associated with low levels of CD39 mRNA and with susceptibility to Crohn’s disease 
[55]. Decreases in CD39 expression levels and consequently adenosine generation 
are likely to be linked to the impairment of CD4+CD25high regulatory T cells [56, 57].  
Such a defect might lead to overwhelming T cell autoreactivity because of the lack of 
immune-modulatory adenosine.  
That adenosine is key in controlling inflammation in IBD, was previously shown by a 
study from Cronstein et al who reported that sulfasalazine, commonly used to treat 
IBD, can inhibit lymphocyte accumulation through an adenosine dependent 
mechanism [58]. Similarly, methotrexate, another drug used in IBD treatment, 
controls inflammation by promoting adenosine release [59]. A subsequent 
investigation demonstrated that the oral administration of ATL313, an agonist of the 
A2A adenosine receptor can attenuate colitis in mice injected with CD45RBhigh cells, 
by suppressing production of pro-inflammatory cytokines (IL-2, IFNγ, TNFα) while 
sparing that of anti-inflammatory (IL-10, TGFβ) cytokines [1]. Later on, a study from 
Frick and coworkers reported that activation of the A2B adenosine receptor is 
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involved in the modulation of the acute phase of DSS colitis in mice through the 
induction of IL-10 by intestinal epithelial cells [60]. 
 
Type 1 diabetes 
There is evidence that adenosine signaling regulates glucose homeostasis through 
the modulation of both insulin and glucagon release [61]. Given the inverse 
correlation between levels of adenosine in the islets and extracellular glucose 
concentration [62] modulation of adenosine signaling by treatment with adenosine 
receptor agonists has been attempted. These investigations showed that treatment 
with the non-selective adenosine receptor agonist 5’ N-ethylcarboxamidoadenosine 
(NECA) prevented the development of diabetes in multiple-low-dose-streptozotocin 
(MLDS)- challenged mice and in NOD mice injected with cyclophosphamide [2].  
The central role of adenosine in preventing the development of diabetes was further 
highlighted by a series of subsequent studies in which A2A adenosine receptor 
knock-out mice were found to be highly susceptible to MSDL-induced diabetes that 
was attenuated following NECA administration [61]. 
A recent study from Johnston-Cox and co-workers in the context of type 2 diabetes 
reported that the A2B adenosine receptor is protective against high fat diet-induced 
insulin resistance. A2B adenosine receptor null mice exposed to high fat diet show 
impaired glucose and insulin homeostasis. Moreover, mice injected with the A2B 
adenosine receptor specific agonist - BAY 60-6583 - displayed lower glucose plasma 
and insulin levels [63]. 
The A2B adenosine receptor is also linked to regulation of hyperlipidemia and 
atherosclerosis. Compared to Apolipoprotein E (ApoE) and A2B adenosine receptor 
knock-out mice, ApoE and A2B adenosine receptor double knock-out mice showed a 
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significant increase in lipid plaques. In vivo administration of BAY 60-6583 in control 
mice on a high fat diet  reduced the lipid profile as well as atherosclerosis [64]. 
 
Multiple sclerosis 
Extracellular adenosine was found to modulate disease progression in mice with 
experimental autoimmune encephalomyelitis (EAE), the mouse model of multiple 
sclerosis. Mice lacking the A2A adenosine receptor developed more severe EAE that 
was characterized by a greater degree of lymphocyte infiltration in the central 
nervous system compared to wild type mice [65].  
That adenosine plays a role in curbing disease activity has been indirectly supported 
by data in patients with multiple sclerosis in whom numerical and functional 
impairment of regulatory T cells expressing CD39 has been reported [66, 67]. 
 
Conclusions    
This review has summarized the role of adenosine in different disease settings such 
as those of hematological malignancies, autoimmunity, chronic and acute respiratory 
disorders, ischemia reperfusion and sepsis and has suggested how pharmacological 
modulation of adenosine generation and signaling could be exploited to treat these 
diverse conditions. The review has highlighted how targeting the adenosinergic axis 
could; 1) control tumor progression and partially overcome the T cell hypo-
responsiveness seen in the tumor setting; 2) modulate the extent of the inflammatory 
infiltrate in asthma and COPD (via adenosine receptor antagonists) and in acute lung 
injury (via adenosine receptor agonists); 3) attenuate damage during ischemia 
reperfusion injury (by increasing breakdown of ATP into adenosine); and 4) control 
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Figure legend. Role of the ecto-enzyme network in cancer models. 
Lymphoma/leukemia cells express the enzymatic machinery necessary to convert 
ATP/ADP into adenosine. Increased extracellular adenosine levels contribute to 
creating a favorable microenvironment by i) inducing cytoprotection in an autocrine 
fashion, by ii) switching off T cell responses and iii) promoting production and 
secretion of soluble mediators of inflammation. Alternatively, adenosine may be 
generated by regulatory T cells, contributing to immunosuppression and effector T 
cell anergy. 
 
 
 
 
 
 
